Shattuck Labs Officer Acquires 12,805 Shares and Warrants Linked to Trial Data

Rhea-AI Filing Summary

Shattuck Labs insider Stephen Stout, the company's General Counsel and Corporate Secretary, acquired 12,805 shares of common stock and accompanying warrants in a private placement that closed on August 25, 2025. The combined price per share and warrant was $0.8677. The warrants allow purchase of up to 12,805 additional shares at an exercise price of $1.0846 and are exercisable from issuance until 30 days after the company publicly announces certain Phase 1 clinical trial data and the design of planned Phase 2 trial(s). Following the transaction, Stout beneficially owns 86,275 shares of common stock.

Insights

Securities Analyst

TL;DR: Insider purchased common stock and warrants in a private placement at $0.8677 per unit.

The filing shows a director and officer, Stephen Stout, participated in a private placement on August 25, 2025, acquiring 12,805 common shares and warrants exercisable at $1.0846. The warrants' exercisability is tied to the public release of Phase 1 clinical data and Phase 2 design information, linking potential dilution to a development milestone. The disclosure reports Stouts beneficial ownership after the transaction as 86,275 shares, which provides transparency on insider holdings but does not include market-impact commentary.

Corporate Governance Expert

TL;DR: Transaction is a routine insider participation in a private placement with milestone-tied warrant terms.

The Form 4 documents a standard securities purchase agreement executed August 4, 2025, and closed August 25, 2025, involving accredited investors including the reporting person. The filing clearly states the number of shares, warrant terms, and the condition that limits warrant exercisability until specific clinical trial data and trial design are publicly announced, which is an explicit, contractually stated condition that stakeholders can monitor.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stout Stephen

(Last) (First) (Middle)

C/O SHATTUCK LABS, INC.

500 W. 5TH STREET, SUITE 1200

(Street)

AUSTIN TX 78701

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Shattuck Labs, Inc. [ STTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2025		A(1)		12,805	A	$0.8677(1)	86,275	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants (Right to Buy)	$1.0846	08/25/2025		A(1)		12,805		(2)	(2)	Common Stock	12,805	(1)	12,805	D

Explanation of Responses:

1. On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 12,805 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 12,805 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.

2. The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.

Remarks:

General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer

	/s/ Stephen Stout	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did STTK insider Stephen Stout acquire on August 25, 2025?

He acquired 12,805 shares of common stock and accompanying warrants to purchase up to 12,805 additional shares.

What was the purchase price per share and warrant in the private placement?

The combined price per share and accompanying warrant was $0.8677.

What is the warrant exercise price and exercisability condition?

The warrants have an exercise price of $1.0846 and are exercisable until 30 days after the company publicly announces specified Phase 1 clinical trial data and Phase 2 trial design.

How many shares does Stephen Stout beneficially own after the transaction?

Following the reported transaction, he beneficially owns 86,275 shares of common stock.

When was the securities purchase agreement executed?

The Purchase Agreement was entered into on August 4, 2025, and the private placement closed on August 25, 2025.